78 research outputs found

    Shedding light on the effect of radiation therapy on circulating tumor cells

    Get PDF
    Many common treatments for cancer – including radiation therapy (RT) – have the unfortunate side effect of promoting the spread of cancer to other organs [1-3]. While the ‘pro-metastatic’ effects of RT have been known for some time, it has garnered renewed attention in recent years in part due to the widespread study of circulating tumor cells (CTCs). In hematogenous metastasis, CTCs detach from the primary tumor and spread via the blood to other organs and tissues of the body. There are three main hypotheses for RT induced metastasis (RTIM) as reviewed in [1]: i) RT causes disruption of the primary tumor and vasculature, which leads to immediate shedding of CTCs, iii) RT induces biomolecular changes in tumor cells, such as epithelial to mesenchymal transition, leading to increased CTC shedding over time as the tumor cells die, and, iii) Systemic effects, such as the elimination of suppressive signaling molecules by the primary tumor resulting in the proliferation of existent but previously dormant micro-metastases [3]. Our team recently developed a new instrument called ‘Diffuse in vivo Flow Cytometry’ (DiFC; figure 1) [4]. The main advantage of DiFC is that it samples large circulating blood volumes (hundreds of µL per minute), allowing in vivo detection of very rare CTCs. DiFC uses specially designed fiber-optic probe bundles with built-in filters and lenses for efficient collection of weak fluorescent signals and blocking of tissue autofluorescence. As labeled cells pass through the DiFC field of view, transient fluorescent peaks are detected. A custom signal processing algorithm allowed us to determine the number, direction, speed, and depth of circulating cells, and reject false alarm signals from motion artifacts. For example, we recently showed that DiFC allowed detection of early dissemination of green fluorescent protein (GFP)-labeled multiple myeloma cells in a disseminated xenograft model at CTC burdens below 1 cell per mL, as well as rare CTC clusters (fig. 1). Please click Additional Files below to see the full abstract

    An Expanded Multi-scale Monte Carlo Simulation Method for Personalized Radiobiological Effect Estimation in Radiotherapy: a feasibility study

    Get PDF
    A novel and versatile “bottom-up� approach is developed to estimate the radiobiological effect of clinic radiotherapy. The model consists of multi-scale Monte Carlo simulations from organ to cell levels. At cellular level, accumulated damages are computed using a spectrum-based accumulation algorithm and predefined cellular damage database. The damage repair mechanism is modeled by an expanded reaction-rate two-lesion kinetic model, which were calibrated through replicating a radiobiological experiment. Multi-scale modeling is then performed on a lung cancer patient under conventional fractionated irradiation. The cell killing effects of two representative voxels (isocenter and peripheral voxel of the tumor) are computed and compared. At microscopic level, the nucleus dose and damage yields vary among all nucleuses within the voxels. Slightly larger percentage of cDSB yield is observed for the peripheral voxel (55.0%) compared to the isocenter one (52.5%). For isocenter voxel, survival fraction increase monotonically at reduced oxygen environment. Under an extreme anoxic condition (0.001%), survival fraction is calculated to be 80% and the hypoxia reduction factor reaches a maximum value of 2.24. In conclusion, with biological-related variations, the proposed multi-scale approach is more versatile than the existing approaches for evaluating personalized radiobiological effects in radiotherapy

    s-RT-MELT for rapid mutation scanning using enzymatic selection and real time DNA-melting: new potential for multiplex genetic analysis

    Get PDF
    The rapidly growing understanding of human genetic pathways, including those that mediate cancer biology and drug response, leads to an increasing need for extensive and reliable mutation screening on a population or on a single patient basis. Here we describe s-RT-MELT, a novel technology that enables highly expanded enzymatic mutation scanning in human samples for germline or low-level somatic mutations, or for SNP discovery. GC-clamp-containing PCR products from interrogated and wild-type samples are hybridized to generate mismatches at the positions of mutations over one or multiple sequences in-parallel. Mismatches are converted to double-strand breaks using a DNA endonuclease (Surveyor™) and oligonucleotide tails are enzymatically attached at the position of mutations. A novel application of PCR enables selective amplification of mutation-containing DNA fragments. Subsequently, melting curve analysis, on conventional or nano-technology real-time PCR platforms, detects the samples that contain mutations in a high-throughput and closed-tube manner. We apply s-RT-MELT in the screening of p53 and EGFR mutations in cell lines and clinical samples and demonstrate its advantages for rapid, multiplexed mutation scanning in cancer and for genetic variation screening in biology and medicine
    corecore